Literature DB >> 33591626

Mesenchymal stromal cells protect hepatocytes from lipotoxicity through alleviation of endoplasmic reticulum stress by restoring SERCA activity.

Linzhao Li1,2, Xin Zeng1, Zhenzhen Liu3, Xuanming Chen1, Lan Li1, Ruixi Luo1, Xiaohong Liu1, Jie Zhang1, Jingping Liu1, Yanrong Lu1, Jingqiu Cheng1, Younan Chen1.   

Abstract

The aim of this study was to investigate how mesenchymal stromal cells (MSCs) modulate metabolic balance and attenuate hepatic lipotoxicity in the context of non-alcoholic fatty liver disease (NAFLD). In vivo, male SD rats were fed with high-fat diet (HFD) to develop NAFLD; then, they were treated twice by intravenous injections of rat bone marrow MSCs. In vitro, HepG2 cells were cocultured with MSCs by transwell and exposed to palmitic acid (PA) for 24 hours. The endoplasmic reticulum (ER) stressor thapsigargin and sarco/ER Ca2+ -ATPase (SERCA2)-specific siRNA were used to explore the regulation of ER stress by MSCs. We found that MSC administration improved hepatic steatosis, restored systemic hepatic lipid and glucose homeostasis, and inhibited hepatic ER stress in HFD-fed rats. In hepatocytes, MSCs effectively alleviated the cellular lipotoxicity. Particularly, MSCs remarkably ameliorated the ER stress and intracellular calcium homeostasis induced by either PA or thapsigargin in HepG2 cells. Additionally, long-term HFD or PA stimulation would activate pyroptosis in hepatocytes, which may contribute to the cell death and liver dysfunction during the process of NAFLD, and MSC treatment effectively ameliorates these deleterious effects. SERCA2 silencing obviously abolished the ability of MSCs against the PA-induced lipotoxicity. Conclusively, our study demonstrated that MSCs were able to ameliorate liver lipotoxicity and metabolic disturbance in the context of NAFLD, in which the regulation of ER stress and the calcium homeostasis via SERCA has played a key role.
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

Entities:  

Keywords:  SERCA; calcium homeostasis; hepatic steatosis; insulin resistance; mesenchymal stromal cells

Year:  2021        PMID: 33591626     DOI: 10.1111/jcmm.16338

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.310


  5 in total

Review 1.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

2.  Human Mesenchymal Stromal Cells Resolve Lipid Load in High Fat Diet-Induced Non-Alcoholic Steatohepatitis in Mice by Mitochondria Donation.

Authors:  Sandra Nickel; Madlen Christ; Sandra Schmidt; Joanna Kosacka; Hagen Kühne; Martin Roderfeld; Thomas Longerich; Lysann Tietze; Ina Bosse; Mei-Ju Hsu; Peggy Stock; Elke Roeb; Bruno Christ
Journal:  Cells       Date:  2022-06-02       Impact factor: 7.666

Review 3.  Mesenchymal Stem Cells and Their Small Extracellular Vesicles as Crucial Immunological Efficacy for Hepatic Diseases.

Authors:  Yuting Tang; Peipei Wu; Linli Li; Wenrong Xu; Jiajia Jiang
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

4.  Activation of the EGFR-PI3K-CaM pathway by PRL-1-overexpressing placenta-derived mesenchymal stem cells ameliorates liver cirrhosis via ER stress-dependent calcium.

Authors:  Se Ho Kim; Jae Yeon Kim; Soo Young Park; Won Tae Jeong; Jin Man Kim; Si Hyun Bae; Gi Jin Kim
Journal:  Stem Cell Res Ther       Date:  2021-10-24       Impact factor: 6.832

5.  Bone marrow derived-mesenchymal stem cell improves diabetes-associated fatty liver via mitochondria transformation in mice.

Authors:  Youkun Bi; Xuejun Guo; Mengqi Zhang; Keqi Zhu; Chentao Shi; Baoqi Fan; Yanyun Wu; Zhiguang Yang; Guangju Ji
Journal:  Stem Cell Res Ther       Date:  2021-12-11       Impact factor: 6.832

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.